These three names get set side by side as if they were three brands of the same thing, three bottles on a shelf, and you simply pick one. They are not the same kind of object at all.
Two of them are medicines. They have been through trials with thousands of men, they are approved by regulators, and we know a great deal about what happens when you use them for years. The third is a research compound. It has never completed a large human trial and it is approved nowhere on earth.
We make the third one. We are going to tell you that anyway, at the top, because a comparison that quietly flattens that difference is not a comparison — it is an advertisement wearing a lab coat.
Here is the fair version.
First: they are not doing the same job
Androgenetic alopecia runs on one chain. Testosterone is converted by 5-alpha-reductase into DHT; DHT binds the androgen receptor inside genetically susceptible follicles; the follicle's growth phase is cut short; the hair it makes gets thinner and shorter with every cycle until it covers nothing. We take that apart properly in why you are losing your hair: DHT, the androgen receptor, and what actually stops it.
What matters here is that each of these three agents attacks a different link:
- Finasteride stops the DHT being made.
- RU-58841 aims to occupy the receptor so the DHT that is made cannot deliver its message.
- Minoxidil ignores the hormone entirely and pushes growth from further down the line.
They are not rivals. They are three different tools, and the question "which one is best" is close to meaningless until you say what you are trying to do and what you are willing to trade.
Finasteride — the brake, at the factory
What it does. Finasteride inhibits type 2 5-alpha-reductase, the enzyme that converts testosterone into DHT. At the standard dose it cuts circulating DHT by roughly two thirds, and scalp DHT substantially. Dutasteride, its bigger sibling, inhibits both enzyme types and suppresses DHT further; it is prescribed for hair loss in some countries and used off-label in others.
The evidence. This is where honesty costs us something. Finasteride has the strongest evidence base of anything in this field by a wide margin — large randomised placebo-controlled trials, five-year follow-up, replicated across populations, measured with hair counts rather than vibes. In those trials the majority of men stopped losing ground and a substantial minority visibly gained some. If your only criterion is "what is most likely to work, according to the best data that exists," the answer is finasteride, and we are not going to dress that up.
The trade. It is systemic. You swallow it, and DHT falls everywhere — not only in the follicles you care about. That is the entire reason a market for topical antiandrogens exists at all.
Side effects, handled honestly. In the trials, sexual side effects — reduced libido, erectile difficulty, ejaculatory changes — were reported at a few percent, and the gap over placebo was a couple of percentage points. Small. Also real. Separately, there are men who report symptoms that did not resolve after stopping; this is discussed as post-finasteride syndrome, it is contested in the literature, its mechanism is not established, and it has nonetheless been reflected in regulatory labelling changes in more than one jurisdiction.
The trial numbers are real. So is the man in the thread. A trial describes what happened to a population; you are one person, and the population figure cannot tell you which person you will be. Anyone who resolves that tension for you — in either direction — is doing it for their own convenience, not yours.
What we will say is this: it is a prescription medicine, and the conversation about whether the trade is right for you belongs with a doctor, not with a vendor and not with a forum.
Minoxidil — the accelerator
What it does. Minoxidil is a potassium channel opener with vasodilatory effects, and after decades of use the honest summary of its mechanism in hair is still "not completely understood." What it demonstrably does is lengthen the growth phase, wake resting follicles, and increase the diameter of the hair a follicle produces.
One detail matters more than the rest: minoxidil is a prodrug. It has to be converted in the scalp into minoxidil sulfate by an enzyme, sulfotransferase, and men vary a great deal in how much of that enzyme their follicles express. This is the leading explanation for why some men respond to minoxidil and some — applying it identically, for a year, with total discipline — get nothing. It is not that they did it wrong. It is that the conversion step did not happen.
The evidence. Strong and old. Approved, over the counter, in most of the world, in topical form. Increasingly used orally at low dose off-label under medical supervision, which is a conversation for a doctor.
Side effects. Scalp irritation and flaking, which is very often the propylene glycol in the vehicle rather than the drug itself — foam formulations exist for exactly this reason. Unwanted hair growth where the solution runs or gets transferred, particularly the face. A shed in the first weeks, which we explain below and which is not the disaster it looks like. Oral minoxidil carries systemic cardiovascular considerations and is not a DIY decision. It is also seriously toxic to cats, which is worth knowing if you have one.
What it cannot do. It never touches the hormone, the enzyme, or the receptor. The DHT signal continues, uninterrupted, the entire time.
It is the accelerator, not the brake — you end up growing hair into a headwind.
This is why minoxidil alone so often plateaus, and why men who spent two years on it alone feel cheated. They were not doing it wrong. It was never fighting the cause; it was compensating for it, and compensation loses eventually.
RU-58841 — the lock, jammed
What it does. RU-58841 is a nonsteroidal androgen receptor antagonist. CAS 154992-24-2. It does not lower your DHT; it competes for the receptor that DHT needs to bind. If it is occupying the seat, the hormone arrives and finds it taken, and the instruction to cut the growth phase short is never transmitted.
It came out of Roussel-Uclaf, and it was designed from the beginning to be applied to skin: to act on the receptor where it lands, and to be broken down rather than build up systemically. In animal models — including primate models of androgenetic hair loss — it did what it was designed to do, with local activity and without the systemic antiandrogenic effect that a swallowed antiandrogen would produce.
Then it stopped. It never became an approved medicine. Why development ended is not publicly documented in any form we would defend. You will find confident explanations on forums and on vendor websites; they are guesses, and usually guesses that flatter whoever is telling them.
The evidence. This is the whole of it, stated without softening:
- There are no large human trials. None. Not buried, not old, not foreign-language — they were not run.
- There is no long-term human safety data, because generating it requires the trial that was not run.
- It is approved nowhere, for anything.
- What exists in humans is anecdote: forum logs, photographs, self-reports. Some of it is careful and honest. It is still anecdote, and it cannot tell you a rate — how often something works, how often something goes wrong — which is the only thing a trial is for.
Side effects. Unknown. Not "none" — unknown, which is a different and more uncomfortable word. Community reports run in both directions, including reports of systemic antiandrogenic symptoms at higher exposures. Anyone who tells you RU-58841 is free of side effects is telling you something they cannot know, and the fact that they are willing to say it should tell you what their other claims are worth.
The one thing we can prove. We cannot show you a trial — nobody can. What we can show you is the bottle: RU-58841 5%, blended by us in the EU, with its batch number and blend date printed on it. That is the whole of our claim, and we would rather state it small than dress it up.
So why do men choose it? Because the reasoning is legible: they want the androgen signal interrupted at the follicle without suppressing DHT throughout their body, and RU-58841 is the best-known compound in that category. That is a rational thing to want. Whether it delivers in humans, at what rate and at what cost, is exactly what has never been established. If you use it, you are accepting an evidence gap in exchange for a route of administration — and you should know that is the trade.
The comparison, in one table
| Finasteride | RU-58841 | Minoxidil | |
|---|---|---|---|
| Target | 5-alpha-reductase (the enzyme) | The androgen receptor | Downstream growth — no androgen target |
| Effect on your DHT | Lowers it, body-wide | Does not lower it — blocks its receptor locally | None |
| Route | Oral — systemic | Topical | Topical (oral off-label) |
| Regulatory status | Approved medicine, prescription | None. Research compound | Approved, over the counter |
| Human evidence | Large RCTs, 5-year data | No large human trials | Large RCTs, decades of use |
| Known side-effect profile | Characterised — low rates in trials, contested persistent reports | Not characterised in humans | Characterised — irritation, unwanted hair, initial shed |
| What it cannot do | Stay local | Show you a trial | Touch the cause |
Read the bottom row again. Those are the three real costs, and every man in this field is choosing which of them he can live with.
Do they combine?
By mechanism, obviously yes. RU-58841 and minoxidil have no shared target — one is trying to silence a signal, the other is trying to extend a growth phase. Stacking them is not a marketing invention; it is what the diagram implies. The same logic is why ketoconazole shampoo turns up in almost every protocol as the cheap third leg — a small anti-androgenic and anti-inflammatory action at the scalp for the price of a shampoo, which we cover in ketoconazole shampoo: the DHT blocker hiding in the shampoo aisle.
Now the honest half of the answer: nobody has run the combination trial. There is no study that tells you RU-58841 plus minoxidil is additive, or safe together over five years, or better than either alone. The logic is sound. The data does not exist. Those are two different statements and we are not going to let one of them stand in for the other.
What we can be held to. Folliva Labs blends RU-58841 5% itself, in the EU, in small batches. It is not bought in and not rebottled. The batch, the blend date and the expiry are printed on the bottle, so you always know how old the thing in your hand is — and for a compound that degrades with time and light, that is not a detail. It ships from inside the EU: days rather than weeks, and a plain box that tells nobody anything.
We can be held to what is in the bottle and how it reached you. We cannot be held to what it will do for you, and we will not pretend otherwise. It is sold for laboratory research.
RU-58841 5% — blended in the EU · The full range
How to actually choose
Not a recommendation — a decision frame. You make the call, ideally with a doctor.
- If your priority is the best-evidenced outcome, and a doctor agrees a systemic medicine is reasonable for you: finasteride is the most evidenced thing on this page. It is not what we sell. It is still the honest answer to that question.
- If your priority is a topical with real trials behind it: minoxidil — understanding that it is the accelerator and does not address the cause.
- If your priority is interrupting the androgen signal at the follicle without a systemic 5-alpha-reductase inhibitor: that is the category RU-58841 sits in, and you are trading away the evidence base to be there. Go in knowing that, or do not go in.
- If you want the cheapest sensible thing tonight: a ketoconazole shampoo, with actual contact time. It is a leg, not the table.
One thing is true of all three, and it is the least popular sentence in this industry: none of them is a cure. Each of them works, to the extent it works, only while you keep using it. Stop, and the follicles resume the trajectory they were on — the cause was never removed, only opposed. That is not a subscription trap. That is what "the cause is still there" means.
And whichever you choose, you cannot assess it by looking in the mirror and feeling hopeful or doomed. Six months is the earliest point a fair judgement is possible, and it has to be made against photographs. We wrote the month-by-month version here: the hair loss timeline — and why most people quit at week three.
Folliva Labs formulates topical research compounds in the EU. This article describes published mechanism and evidence. It is not medical advice, not a comparison of medicines for the purpose of recommending one, and not a claim that any product prevents, treats or cures any condition. Finasteride and minoxidil are medicines — discuss them with a doctor. RU-58841 is sold for laboratory research: not for human or veterinary use.